EpCAM tumor specificity and proteoform patterns in urothelial cancer
Open Access
- 8 May 2023
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (11) , 8913-8922
Abstract
Background: The role of the epithelial cell adhesion molecule (EpCAM) in cancer is still unclear. EpCAM cleavage through regulated intramembrane proteolysis results in fragments which interact with both oncogenic and tumor suppressive pathways. Additionally, the EpCAM molecule itself is used as a descriptive therapeutic target in urothelial cancer (UC), while data on its actual tumor specificity remain limited.Methods: Samples from diagnostic formalin-fixed paraffin-embedded (FFPE) UC tissue and fresh-frozen UC cells were immunoblotted and used for qualitative characterization of five different EpCAM fragments. These expression patterns were quantified across a cohort of 76 samples with 52 UC and 24 normal urothelial samples. Cell viability effects of the extracellular EpEX fragment were assessed in the UC cell lines T24 and HT1376.Results: The proteolytic EpCAM fragments could be identified in clinical FFPE tissue specimens too. Neither overall nor fragment-specific EpCAM expression showed relevant tumor specificity. EpEX and its deglycosylated variant showed an inverse relationship across healthy and tumor tissue with a decrease of deglycosylated EpEX in tumors. However, extracellular EpEX did not show a relevant effect in vitro.Conclusions: EpCAM should not be regarded as tumor-specific in UC without patient-specific predictive testing. EpCAM fragment patterns indicate cancer-specific changes and could be involved in its complex tumor-biological role.Keywords
Funding Information
- Else Kröner-Fresenius-Stiftung (2018_A84, 2018_A84)
- Charité - Universitätsmedizin Berlin
This publication has 49 references indexed in Scilit:
- EpCAM: Structure and function in health and diseaseBiochimica et Biophysica Acta (BBA) - Biomembranes, 2013
- EpCAM proteolysis: new fragments with distinct functions?Bioscience Reports, 2013
- Circulating Tumor Cells: Liquid Biopsy of CancerClinical Chemistry, 2013
- EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysisJournal of Clinical Pathology, 2011
- A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patientsDrug Design, Development and Therapy, 2010
- An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancerAnnals of Oncology, 2010
- Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndromeGenes, Chromosomes and Cancer, 2009
- EpCAM expression in normal, non-pathological tissuesFrontiers in Bioscience-Landmark, 2008
- Glycosylation is crucial for stability of tumour and cancer stem cell antigen EpCAMFrontiers in Bioscience-Landmark, 2008
- Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment IIHistopathology, 2006